Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or metastatic breast cancer: An open-label, randomized, controlled phase II study.

Authors: Jiayu Wang, Quchang Ouyang, Xiying Shao, Wenbin Zhou, Yongsheng Wang, Weimin Xie, Jingfen Wang, Aimei Jiang, Changwen Li, Zerui Qu, Chenran Han, Bo Yang, Jianmin Fang, Binghe Xu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps1139

Source: Full article

---

Abstract

TPS1139